{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:56:14Z","timestamp":1793321774460,"version":"4.5.0"},"reference-count":46,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,9,30]],"date-time":"2021-09-30T00:00:00Z","timestamp":1632960000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016036","name":"Health~Holland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016036","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>The influence of hypercortisolism on phosphate homeostasis is relatively unknown. A few previous studies have reported on patients with Cushing\u2019s syndrome (CS) with hypophosphatemia in whom serum phosphate normalized after initiation of treatment for CS. We aimed to investigate the prevalence of hypophosphatemia in CS, the association between the degree of hypercortisolism and serum phosphate and the change in serum phosphate after remission of CS. We compared the prevalence of hypophosphatemia in CS with the prevalence in the population-based Rotterdam Study (RS).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients diagnosed with CS and treated at the Department of Endocrinology of Erasmus MC in the period of 2002-2020 were included and data was collected on age at diagnosis, sex, serum phosphate, calcium and potassium levels, kidney function and BMI. Using multivariate linear regression, we analyzed the association between 24h urinary free cortisol excretion (UFC) and serum phosphate. Changes in serum phosphate and covariates were tested with a repeated measurement ANOVA, using mean levels of laboratory values for the periods before remission, and 0-14 days and 15-180 days after remission.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Hypophosphatemia before treatment was present in 16% of the 99 CS patients with data on serum phosphate, 24h UFC and covariates. In comparison, the prevalence of hypophosphatemia in RS was 2.0-4.2%. Linear regression showed a negative association between the level of UFC and serum phosphate at diagnosis, which remained significant after adjusting for covariates [\u03b2 -0.002 (95%CI -0.004; -0.0004), p=0.021]. A subset of 24 patients had additional phosphate measurements at 0-14 days and 15-180 days after remission. In this subgroup, serum phosphate significantly increased from 1.03 \u00b1 0.17 mmol\/L prior to remission to 1.22 \u00b1 0.25 mmol\/L 15-180 days after remission (<jats:italic>p<\/jats:italic> = 0.008). BMI decreased after remission [-1.1 kg\/m<jats:sup>2<\/jats:sup>, (95%CI -2.09 to -0.07), p=0.037]. Other covariates did not show an equivalent change over time.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In this retrospective study, we found that 16% of patients with CS had hypophosphatemia. Moreover, serum phosphate was related to the level of cortisoluria and increased after remission of CS. Potential underlying mechanisms related to urinary phosphate excretion and possibly involving FGF23, BMI and parathyroid hormone levels should be further explored.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2021.733793","type":"journal-article","created":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T04:53:49Z","timestamp":1633064029000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Cortisol and Phosphate Homeostasis: Cushing\u2019s Syndrome Is Associated With Reversible Hypophosphatemia"],"prefix":"10.3389","volume":"12","author":[{"given":"Ariadne","family":"Bosman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annewieke W.","family":"van den Beld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Feelders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Carola","family":"Zillikens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,9,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61375-1","article-title":"Cushing\u2019s Syndrome","volume":"386","author":"Lacroix","year":"2015","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1210\/er.2018-00097","article-title":"Glucocorticoids and Bone: Consequences of Endogenous and Exogenous Excess and Replacement Therapy","volume":"39","author":"Hardy","year":"2018","journal-title":"Endocr Rev"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.4033","article-title":"The Effect of Biochemical Remission on Bone Metabolism in Cushing\u2019s Syndrome: A Two-Year Follow-Up Study","volume":"35","author":"Braun","year":"2020","journal-title":"J Bone Miner Res"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcq039","article-title":"Medication-Induced Hypophosphatemia: A Review","volume":"103","author":"Liamis","year":"2010","journal-title":"Qjm"},{"key":"B5","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1210\/jc.2011-1319","article-title":"Approach to the Hypophosphatemic Patient","volume":"97","author":"Imel","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1988.00380010155016","article-title":"Severe Hypophosphatemia in Hospitalized Patients","volume":"148","author":"Halevy","year":"1988","journal-title":"Arch Intern Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1100\/tsw.2008.20","article-title":"Hypophosphatemia as Unusual Cause of ARDS in Cushing\u2019s Syndrome Secondary to Ectopic CRH Production","volume":"8","author":"Mondello","year":"2008","journal-title":"A Case Rep Sci World J"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-011-9527-8","article-title":"Hypophosphatemia Related to Paraneoplastic Cushing Syndrome in Prostate Cancer: Cure After Bilateral Adrenalectomy","volume":"89","author":"Ramon","year":"2011","journal-title":"Calcif Tissue Int"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-54-5-1039","article-title":"Vitamin D Metabolites and Parathyroid Hormone in Cushing\u2019s Syndrome: Relationship to Calcium and Phosphorus Homeostasis","volume":"54","author":"Findling","year":"1982","journal-title":"J Clin Endocrinol Metab"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1136\/jclinpath-2018-205130","article-title":"Disorders of Phosphate Metabolism","volume":"72","author":"Leung","year":"2019","journal-title":"J Clin Pathol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2008.02.014","article-title":"Clinical Usefulness of Measurement of Fibroblast Growth Factor 23 (FGF23) in Hypophosphatemic Patients: Proposal of Diagnostic Criteria Using FGF23 Measurement","volume":"42","author":"Endo","year":"2008","journal-title":"Bone"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.3761","article-title":"Glucocorticoids Decrease Longitudinal Bone Growth in Pediatric Kidney Transplant Recipients by Stimulating the FGF23\/FGFR3 Signaling Pathway","volume":"34","author":"Delucchi","year":"2019","journal-title":"J Bone Miner Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.87.6.8688","article-title":"Molecular Pathogenesis of Hypophosphatemic Rickets","volume":"87","author":"Jan de Beur","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s00590-014-1496-y","article-title":"Hypophosphatemic Rickets: Etiology, Clinical Features and Treatment","volume":"25","author":"Pavone","year":"2015","journal-title":"Eur J Orthop Surg Traumatol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1007\/s11914-015-0259-y","article-title":"Hypophosphatemic Rickets: Lessons From Disrupted FGF23 Control of Phosphorus Homeostasis","volume":"13","author":"Goldsweig","year":"2015","journal-title":"Curr Osteoporos Rep"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/ncpneph0124","article-title":"Hypophosphatemia: An Evidence-Based Approach to Its Clinical Consequences and Management","volume":"2","author":"Amanzadeh","year":"2006","journal-title":"Nat Clin Pract Nephrol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-physiol-030212-183748","article-title":"Phosphate Transporters and Their Function","volume":"75","author":"Biber","year":"2013","journal-title":"Annu Rev Physiol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s10654-020-00640-5","article-title":"Objectives, Design and Main Findings Until 2020 From the Rotterdam Study","volume":"35","author":"Ikram","year":"2020","journal-title":"Eur J Epidemiol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A New Equation to Estimate Glomerular Filtration Rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-1818","article-title":"Treatment of Cushing\u2019s Syndrome: An Endocrine Society Clinical Practice Guideline","volume":"100","author":"Nieman","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1530\/EC-20-0509","article-title":"Age-Dependent Sex Differences in Calcium and Phosphate Homeostasis","volume":"10","author":"Koek","year":"2021","journal-title":"Endocr Connect"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.4103\/2230-8210.117215","article-title":"Glucocorticoid-Induced Myopathy: Pathophysiology, Diagnosis, and Treatment","volume":"17","author":"Gupta","year":"2013","journal-title":"Indian J Endocrinol Metab"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1096\/fj.201600473R","article-title":"Hypophosphatemia Promotes Lower Rates of Muscle ATP Synthesis","volume":"30","author":"Pesta","year":"2016","journal-title":"FASEB J"},{"key":"B24","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgab058","article-title":"Acute and Life-Threatening Complications in Cushing Syndrome: Prevalence, Predictors, and Mortality","volume":"106","author":"Schernthaner-Reiter","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"B25","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s00109-021-02036-8","article-title":"Glucocorticoids Dexamethasone and Prednisolone Suppress Fibroblast Growth Factor 23 (FGF23)","volume":"99","author":"Feger","year":"2021","journal-title":"J Mol Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1172\/JCI118022","article-title":"Dexamethasone Modulates Rat Renal Brush Border Membrane Phosphate Transporter mRNA and Protein Abundance and Glycosphingolipid Composition","volume":"96","author":"Levi","year":"1995","journal-title":"J Clin Invest"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)68699-6","article-title":"Cushing\u2019s Syndrome","volume":"367","author":"Newell-Price","year":"2006","journal-title":"Lancet"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2002-021558","article-title":"Cardiovascular Risk Factors and Common Carotid Artery Caliber and Stiffness in Patients With Cushing\u2019s Disease During Active Disease and 1 Year After Disease Remission","volume":"88","author":"Faggiano","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.84.8.5896","article-title":"Persistence of Increased Cardiovascular Risk in Patients With Cushing\u2019s Disease After Five Years of Successful Cure","volume":"84","author":"Colao","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2008.08.018","article-title":"Serum Phosphate Levels and the Risk of Cardiovascular Disease and Metabolic Syndrome: A Double-Edged Sword","volume":"83","author":"Park","year":"2009","journal-title":"Diabetes Res Clin Pract"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1111\/eci.12769","article-title":"Serum Phosphate Is Related to Adiposity in Healthy Adults","volume":"47","author":"Billington","year":"2017","journal-title":"Eur J Clin Invest"},{"key":"B32","doi-asserted-by":"publisher","first-page":"e1001383","DOI":"10.1371\/journal.pmed.1001383","article-title":"Causal Relationship Between Obesity and Vitamin D Status: Bi-Directional Mendelian Randomization Analysis of Multiple Cohorts","volume":"10","author":"Vimaleswaran","year":"2013","journal-title":"PloS Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-2280","article-title":"Serum Leptin, Parathyroid Hormone, 1,25-Dihydroxyvitamin D, Fibroblast Growth Factor 23, Bone Alkaline Phosphatase, and Sclerostin Relationships in Obesity","volume":"97","author":"Grethen","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.65","article-title":"Leptin Stimulates Fibroblast Growth Factor 23 Expression in Bone and Suppresses Renal 1alpha,25-Dihydroxyvitamin D3 Synthesis in Leptin-Deficient Mice","volume":"25","author":"Tsuji","year":"2010","journal-title":"J Bone Miner Res"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.clnu.2016.12.010","article-title":"Associations of Serum Fibroblast Growth Factor 23 Levels With Obesity and Visceral Fat Accumulation","volume":"37","author":"Hu","year":"2018","journal-title":"Clin Nutr"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1530\/eje.1.02040","article-title":"Glomerular Filtration Rate in Patients With Cushing\u2019s Disease: A Matched Case-Control Study","volume":"153","author":"Haentjens","year":"2005","journal-title":"Eur J Endocrinol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1007\/s10157-014-0962-5","article-title":"Assessment of Tubular Reabsorption of Phosphate as a Surrogate Marker for Phosphate Regulation in Chronic Kidney Disease","volume":"19","author":"Hong","year":"2015","journal-title":"Clin Exp Nephrol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.90765.2008","article-title":"Differential Regulation of the Renal Sodium-Phosphate Cotransporters NaPi-IIa, NaPi-IIc, and PiT-2 in Dietary Potassium Deficiency","volume":"297","author":"Breusegem","year":"2009","journal-title":"Am J Physiol Renal Physiol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa359","article-title":"Effects of Potassium or Sodium Supplementation on Mineral Homeostasis: A Controlled Dietary Intervention Study","volume":"105","author":"Humalda","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(16)00086-3","article-title":"Complications of Cushing\u2019s Syndrome: State of the Art","volume":"4","author":"Pivonello","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-019-04906-x","article-title":"Glucocorticoid-Induced Osteoporosis: 2019 Concise Clinical Review","volume":"30","author":"Adami","year":"2019","journal-title":"Osteoporos Int"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22063131","article-title":"Cushing\u2019s Syndrome Effects on the Thyroid","volume":"22","author":"Paragliola","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1210\/endo.140.4.6658","article-title":"Role of Thyroid Hormone in Regulation of Renal Phosphate Transport in Young and Aged Rats","volume":"140","author":"Alcalde","year":"1999","journal-title":"Endocrinology"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2009.05231.x","article-title":"ACTH Is a Novel Regulator of Bone Mass","volume":"1192","author":"Isales","year":"2010","journal-title":"Ann N Y Acad Sci"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0912176107","article-title":"ACTH Protects Against Glucocorticoid-Induced Osteonecrosis of Bone","volume":"107","author":"Zaidi","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2014.04.028","article-title":"Serum Phosphorus and Mortality in the Third National Health and Nutrition Examination Survey (NHANES III): Effect Modification by Fasting","volume":"64","author":"Chang","year":"2014","journal-title":"Am J Kidney Dis"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2021.733793\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T04:53:53Z","timestamp":1633064033000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2021.733793\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,30]]},"references-count":46,"alternative-id":["10.3389\/fendo.2021.733793"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2021.733793","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,30]]},"article-number":"733793"}}